Galectin Therapeutics Inc (NASDAQ:GALT) does about 434.43K shares in volume on a normal day but saw 2785295 shares change hands in the recent trading day. The company now has a market cap of 55.46M USD. Its current market price is $0.89, marking a decrease of -14.41% compared to the previous close of $1.04. The 52 week high reached by this stock is $4.27 whilst the lowest price level in 52 weeks is $0.73.
Galectin Therapeutics Inc (GALT) has a 20-day trading average at $2.1688 and the current price is -79.15% off the 52-week high compared with 22.60% distance from its 52-week low. The 50-day simple moving average of the closing price is $2.4758 and its 200-day simple moving average is $2.6371. If we look at the stock’s price movements over the week, volatility stands at 30.25%, which decreases to 14.36% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 19.45 to suggest the stock is oversold.
The consensus objective for the share price is $11.00, suggesting that the stock has a potential upside of 91.91% over the period.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on August 13, 2020 when H.C. Wainwright reiterated the stock to “Buy” and issued a price target of between $9 and $12. H.C. Wainwright reiterated its price target at $6-$10.
The current price level is -58.96%, -64.05%, and -66.25% away from its SMA20, SMA50, and SMA200 respectively, with the GALT price moving above the 50-day SMA on current market day. Galectin Therapeutics Inc (GALT) stock is down -61.47% over the week and -67.28% over the past month. Its price is -46.38% year-to-date and -49.99% over the past year.
The company’s next earnings report forecasts estimating quarterly EPS at 0 and 0 for whole year.
To reach the target analysts have set, the stock logically needs to grow 91.91 percent from here.
Outstanding shares total 62.31M with insiders holding 30.95% of the shares and institutional holders owning 15.77% of the company’s common stock. The company has a return on investment of -2675.95%. The beta has a value of 0.82.
